Form 8-K PDL BIOPHARMA, INC. For: Feb 09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
�
�
FORM 8-K
�
�
CURRENT REPORT
�
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
�
Date of Report (Date of Earliest Event Reported): February 9, 2015
�
PDL BioPharma, Inc.
�
(Exact name of Company as specified in its charter)
�
000-19756
(Commission File Number)
�
� |
� |
� |
Delaware |
� |
94-3023969 |
(State or Other Jurisdiction of |
� |
(I.R.S. Employer Identification No.) |
Incorporation) |
� |
� |
�
932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)
�
(775) 832-8500
(Companys telephone number, including area code)
�
�
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
�
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
� | � |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
� | � |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
� | � |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
�
�
�
Item 7.01 Regulation FD Disclosure.
�
On February 9, 2015, PDL BioPharma, Inc. (the Company) will make a presentation at, and participate in conferences with investors and analysts during, the 2015 BIO CEO & Investor Conference in New York, New York. A copy of the Companys presentation materials has been posted to the Companys website and is attached hereto as Exhibit 99.1.
�
Limitation of Incorporation by Reference
�
In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.
�
Cautionary Statements
�
This filing and the presentation include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Companys royalty assets or business are disclosed in the Risk Factors contained in the Companys 2013 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 3, 2014, as updated by subsequent periodic filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.
�
Item 9.01 Financial Statements and Exhibits.
�
(d) Exhibits.
�
Exhibit No. |
� |
Description |
99.1 |
� |
Presentation |
�
�
SIGNATURES
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
�
�
� |
PDL BioPharma, inC. |
� | |
� |
(Company) |
� | |
� |
� |
� |
� |
� |
By: |
/s/ John P. McLaughlin |
� |
� |
� |
John P. McLaughlin |
� |
� |
� |
President and Chief Executive Officer |
� |
�
�
Dated: February 9, 2015
�
�
Exhibit Index
�
Exhibit No. |
� |
Description |
99.1� |
� |
Presentation |
�
Exhibit 99.1
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Company announcement no 8 Idavang 2024 Annual General Meeting 26-04-2024
- Offentliggørelse af prospekt samt formue og investorer for afdelingen HP Invest Bolig i Investeringsforeningen Wealth Invest
- HSBC Continental Europe: Post Stabilisation Notice
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!